ESMO 2017 Highlights in Supportive and Palliative Care: Focus on Patient Reported Outcomes

Speaker: Karin Jordan

Karin Jordan says that supportive and palliative care issues are becoming increasingly important in oncology practice and that an ESMO position paper on this topic will be coming soon. 

Karin Jordan says that supportive and palliative care issues are becoming increasingly important in oncology practice and that an ESMO position paper on this topic will be coming soon. She also explains that listening to what the patients says and not only considering what the physician reports should be considered and trials need to include quality of life questionnaires to include this very important dimension of the clinical data.

Christina Ruhlmann reports on the results of a multinational randomised trial conducted in patients with cervical cancer to test if the addition of fosaprepitant would reduce the impact of nausea during the 5 weeks of chemoradiotherapy. Fewer emetic events were reported in the active group and there was a clear benefit regarding the impact on daily function.

Yvonne Brandberg presents the results from the Panther trial which showed that there was no strong correlation between the physician’s and the patient’s scoring regarding toxicity and quality of life reporting.

Abstracts

  • 1540O - Fosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy – a sub-study of the GAND-emesis trial
  • 1422O - CTCA toxicity scoring and EORTC Quality of Life Questionnaire – a comparison of physicians’ and patients’ scoring of toxicity in the "Panther trial"

More resources from ESMO 2017 Congress